21 CFR 211.180(e) - Annual Product Review

What it says

Written records for each drug product must be reviewed annually to evaluate the quality standards of the drug product, determine whether changes to specifications or manufacturing procedures are warranted, and identify trends across batches, covering elements including batch failures, complaints, returns, recalls and stability data.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• The Annual Product Review is the point where a manufacturer is expected to step back from individual batch and deviation records and look for patterns across a full year of production, something no single batch record review can reveal on its own.
• This review functions as a structured trending exercise, connecting batch failures, complaints, stability results and deviations that might look unrelated in isolation but reveal a systemic issue when examined together.
• Findings from an Annual Product Review frequently trigger a reassessment of specifications or manufacturing procedures, linking this provision to both the change control system and the deviation management system.

What FDA inspectors look for

• Whether an Annual Product Review was actually completed for each product within the required timeframe, covering all the required data sources.
• Whether trends identified during the review, such as a rising complaint rate or recurring deviation type, led to a documented evaluation and, where warranted, a corrective action.
• Whether the review genuinely synthesizes data across the full review period rather than simply restating individual batch outcomes without analysis.

Related regulations